Investor Alert: Crucial Biotech Patents May Signal $13B Breakthrough

Profitable Biotech Enters the Race to Treat Alzheimer's ... ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe A Message from i2i Marketing Group, LLC Dear Investor, You're about to discover what could become one of the leaders in the race to treat Alzheimer's. Why? It's Alzheimer's treatment, is nearing Phase 2 trials and is showing remarkable potential. It's unlike any pill or treatment you've ever heard of. That's because this company has literally patented a molecule that may not only treat but has been shown to reverse Alzheimer's in early studies. But this biotech is smart. Its patented molecules block competitors from creating knockoffs. It's a strategic advantage that could make early investors very happy one day. With buyouts getting bigger than ever in biotech and Big Pharma spending billions to buyout competitors... now is the time to move this one stock to the top of your watchlist. Not only that... With FDA approvals accelerating and the Alzheimer's market growing at 20% annually, this stock could be poised for significant growth. Take a closer look at this biotech.   This message is a paid advertisement sent on behalf of i2i Marketing Group, LLC, a third-party advertiser of MarketBeat. Why did I receive this email?     This message is a paid advertisement for InMed Pharmaceuticals (NASDAQ: INM) from i2i Marketing Group, LLC and Summit Publishing. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $7,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either i2i Marketing Group, LLC or Summit Publishing. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding InMed Pharmaceuticals (NASDAQ: INM) on Summit Publishing' website for additional information about the relationship between Summit Publishing and InMed Pharmaceuticals (NASDAQ: INM).     If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.   © 2006-2024 MarketBeat Media, LLC. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.